These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21971618)

  • 1. [Erythropoietinin oncologic therapy -- what so we know about the risks?].
    Leo C; Fink D
    Praxis (Bern 1994); 2011 Oct; 100(20):1239-46. PubMed ID: 21971618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of human recombinant erythropoietin in oncologic surgery].
    Mercuriali F
    Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and the anemia of cancer.
    Beguin Y
    Acta Clin Belg; 1996; 51(1):36-52. PubMed ID: 8669161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin for oncology supportive care.
    McKinney M; Arcasoy MO
    Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
    Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
    Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
    Quirt I; Micucci S; Moran LA; Pater J; Browman G
    Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment.
    Adamson JW; Spivak JL
    Surgery; 1994 Jan; 115(1):7-15. PubMed ID: 8284765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute postoperative anemia with recombinant human erythropoietin.
    Levine EA; Rosen AL; Sehgal LR; Gould SA; Egrie JC; Sehgal HL; Moss GS
    J Trauma; 1989 Aug; 29(8):1134-8; discussion 1138-9. PubMed ID: 2760953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
    Crawford J
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.